80483-86-9

Upstream product

• 55357-38-5 choline tosylate 
• 80707-93-3 (S)-1-O-octadecyl-2-O-benzyl-glycerol 
• 112-92-5 1-octadecanol 
• 80459-32-1 (2R)-2-Benzyloxy-3-octadecyloxypropyl 2-bromoethyl phosphate 
• 75-50-3 trimethylamine 
• 84379-56-6 1-O-octadecyl-2-O-benzyl-3,4-O-isopropylidene-D-threitol 
• 84379-58-8 1-O-octadecyl-2-O-benzyl-D-threitol 
• 100-52-7 benzaldehyde 
• 91326-83-9 (4S,5S)-dimethyl 2-phenyl-1,3-dioxolane-4,5-dicarboxylate 
• 84379-52-2 (2R,3R)-3-(benzyloxy)butane-1,2,4-triol 
• 84379-54-4 (R)-2-(benzyloxy)-2-[(R)-2,2-dimethyl-1,3-dioxolan-4-yl]ethanol 
• 31081-59-1 1-octadecyl methanesulfonate 
• 80459-30-9 2-O-Benzyl-1-O-octadecyl-3-O-trityl-sn-glycerin 
• 83526-60-7 2-O-Acetyl-1-O-benzyl-3-O-octadecyl-sn-glycerin 

Downstream Products

• 74430-89-0 Lyso-platelet-activating factor (C₁₈) 
• 74389-69-8 1-O-octadecyl-2-acetyl-sn-glycero-3-phosphocholine 

Relevant academic research and scientific papers

Synthesis and biological activity of anticancer ether lipids that are specifically released by phospholipase A2 in tumor tissue

The clinical use of anticancer lipids is severely limited by their ability to cause lysis of red blood cells prohibiting intravenous injection. Novel delivery systems are therefore required in order to develop anticancer ether lipids (AELs) into clinicall

Method of use of 1-(alkyl for alkylcarbanoyl)-2-carbamoylglycerol derivatives

Glycerol derivatives, inclusive of salts thereof, of the formula STR1 wherein R1 is alkyl or alkylcarbamoyl containing 10 to 30 carbon atoms, R2 and R3 are independently hydrogen, C1-6 alkyl or, taken together w